Verapamil SR and trandolapril combination therapy is safe and effective inhypertensive patients with metabolic disorders

Verapamil SR (180 mg) plus trandolapril (2 mg) is a potent antihypertensive combination but the efficacy and safety of this treatment has not been stu died fully in hypertensive patients with metabolic disorders. We enrolled 2 98 patients with mild to moderate hypertension who had at least one of the following disorders: diabetes mellitus, hypercholesterolaemia or mild renal failure. The sitting systolic pressure and diastolic blood pressures were significantly decreased after 12 weeks of treatment. Blood pressure was ina dequately controlled in only 24 patients (8.8%). Progressive decreases in b lood glucose, total cholesterol, low-density lipoprotein and triglyceride l evels were observed during the study. There was no significant change in bl ood urea nitrogen, creatinine and transaminase levels (p>0.05). There was a significant decrease in microalbuminuria levels. There was no significant change in glycosylated haemoglobin levels in diabetic patients. Verapamil S R plus trandolapril is an effective drug combination in the treatment of hy pertension. It may be used safely in patients with diabetes mellitus, hyper lipidaemia and mild renal failure.